We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ablynx Identifies Nanobodies® Achieving Second Milestone in Procter & Gamble Collaboration
News

Ablynx Identifies Nanobodies® Achieving Second Milestone in Procter & Gamble Collaboration

Ablynx Identifies Nanobodies® Achieving Second Milestone in Procter & Gamble Collaboration
News

Ablynx Identifies Nanobodies® Achieving Second Milestone in Procter & Gamble Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ablynx Identifies Nanobodies® Achieving Second Milestone in Procter & Gamble Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ablynx has announced that its collaboration agreement with Procter & Gamble Pharmaceuticals Inc. (P&GP), a division of The Procter & Gamble Company, has reached a second milestone.

Ablynx has discovered novel Nanobodies® against a second target for possible new treatments in the musculoskeletal area. The first milestone under this collaboration was achieved in December 2006 and was also a target for musculoskeletal diseases.

Ablynx’s patented Nanobody® technology has been used to identify a highly diverse and potent panel of Nanobodies® against one of the targets exclusive to the collaboration, triggering a second undisclosed milestone payment.

Hennie R. Hoogenboom, PhD, Chief Scientific Officer at Ablynx, said: “We are delighted to have met another important milestone as part of our on-going collaboration with Procter & Gamble. This is yet another important validation of the speed at which our Nanobody® technology platform can deliver high quality Nanobodies®. We are very excited to advance this programme to the next stage together with Procter & Gamble.”

Kevin E. Driscoll, PhD, Director New Technology Development at P&GP added: “We are very pleased with the progression of our collaboration with Ablynx. We are a step closer towards the goal of producing Nanobody® development candidates in this very important area of musculoskeletal diseases.”

As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies® that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies®, as well as the commercialization of any resulting drug products.

Ablynx’ strategy is to build a diverse and broad portfolio of therapeutic Nanobodies® based on strategic partnerships as well as on its own internal discovery pipeline.

Advertisement